Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EHA 2018 /
Interim results of RELEVANCE trial in follicular lymphoma

14th - 17th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.06.18
Views: 748
Rating:

Prof Franck Morschhauser - Hôpital Claude Huriez, Lille, France

Prof Morschhauser speaks with ecancer at EHA 23 about the treating FL with rituximab added to chemoimmunotherapy.

These are interim findings, and Prof Morschhauser sets out the timeline for further data to be reported.

For more information, watch his presentation of this data at a press session here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation